Targeting Blood-Brain Barrier Damage with Nanotechnology in the Fight Against Neurodegenerative Diseases

Rajeshwar, V. and Ronald Darwin, C. and Ilango, K. and Iswariya, V.T. and Begum, Shaik. Shafiya and Mohan, Vasanth Kumar (2026) Targeting Blood-Brain Barrier Damage with Nanotechnology in the Fight Against Neurodegenerative Diseases. CNS & Neurological Disorders - Drug Targets, 25. ISSN 18715273

Full text not available from this repository.

Abstract

Targeting Blood-Brain Barrier Damage with Nanotechnology in the Fight Against Neurodegenerative Diseases V. Rajeshwar https://orcid.org/0000-0002-4251-5550 C. Ronald Darwin https://orcid.org/0000-0002-2731-8196 K. Ilango https://orcid.org/0000-0003-2241-2965 V.T. Iswariya https://orcid.org/0000-0003-2282-2438 Shaik. Shafiya Begum https://orcid.org/0009-0009-6952-8106 Vasanth Kumar Mohan https://orcid.org/0000-0002-2482-8916 Abstract:

The global health burden is attributed to neurodegenerative diseases, of which Alzheimer’s disease and Parkinson’s disease represent the major NDs. Changes in the blood-brain barrier system are considered an important mechanism in the pathogenesis of neurodegeneration, a process increasingly recognised. This review critically evaluates the recent advancement in nanotechnology that aims at targeting and recovering BBB disruption in neurodegenerative diseases. Nanoparticles, including polymeric, liposomal, micellar, metallic, and carbon-based systems, have the potential to cross the BBB. These mechanisms happen through receptor-mediated and adsorptive- mediated transcytosis. These nanoparticles also assist in repairing the BBB and allowing for protein expression. To counteract oxidative stress and alter inflammatory pathways. These nano systems are adept at drug control, neurovascular unit stability, and bioavailability enhancement of various medicines. Nanotechnology provides a dual advantage for therapy and active repairing. It can deliver drugs to the CNS selectively. The technology can actively repair the BBB structure and function. Further interdisciplinary research, translations, and safety assessments are essential to realize the full clinical promise of nanomedicine for the management of neurodegenerative diseases.
03 26 2026 LiveAll1 1 10.2174/BSP_crossmark_policy eurekaselect.com true Peer Reviewed Double blind Checked with iThenticate 2025-08-25 2025-11-25 2025-12-01 2026-03-26 10.2174/0118715273433580260209213317 https://www.eurekaselect.com/251489/article https://www.eurekaselect.com/251489/article https://www.eurekaselect.com/article/download?doi=10.2174/0118715273433580260209213317 https://www.eurekaselect.com/article/download?doi=10.2174/0118715273433580260209213317 https://www.eurekaselect.com/article/download?doi=10.2174/0118715273433580260209213317 https://www.eurekaselect.com/article/download?doi=10.2174/0118715273433580260209213317 https://www.eurekaselect.com/article/download?doi=10.2174/0118715273433580260209213317 https://www.eurekaselect.com/article/download?doi=10.2174/0118715273433580260209213317 https://www.eurekaselect.com/251489/article

Item Type: Article
Subjects: Pharmacology > Drug Delivery Systems
Domains: Pharmacology
Depositing User: Prabakaran Natarajan
Date Deposited: 10 Sep 2026 07:24
Last Modified: 10 Sep 2026 07:24
URI: https://ir.vistas.ac.in/id/eprint/23029

Actions (login required)

View Item
View Item